Drug profile

The FDA adverse-event record for Canine Distemper Virus + Adenovirus + Parvovirus Vaccine

13 adverse-event reports submitted to the FDA Center for Veterinary Medicine reference Canine Distemper Virus + Adenovirus + Parvovirus Vaccine. See the species affected, top reactions, and outcomes below.

13
adverse-event reports
7.7%
death-coded share
Dog
most-reported species
4
Other abnormal test result NOS - top reaction
Verify with FDA CVM →
Important: Adverse event reports do not establish that a drug caused or contributed to the event. Consult your veterinarian before making treatment decisions.
13
Total Reports
1
Deaths Reported
7.7%
Death Rate

Active Ingredients

Canine Distemper Virus + Adenovirus + Parvovirus Vaccine

Administration Routes

UnknownParenteralSubcutaneous

Species Affected

Dog 13

Most Affected Breeds

Terrier - Yorkshire 2
Terrier (unspecified) 2
Akita 1
Retriever - Golden 1
Spaniel - King Charles Cavalier 1
Dog (unknown) 1
Beagle 1
Terrier - Jack Russell 1
Schnauzer - Miniature 1
Maltese 1

Most Reported Reactions

Other abnormal test result NOS 4
Weight loss 2
Hypoproteinaemia 2
Hyperphosphataemia 2
Lack of efficacy (endoparasite) - heartworm 2
Seizure NOS 2
Leucocytosis NOS 2
Neutrophilia 2
Injection site pain 2
Abnormal radiograph finding 1
Low creatinine 1
Low blood urea nitrogen (BUN) 1

Outcome Breakdown

Ongoing
6 (46.2%)
Outcome Unknown
6 (46.2%)
Died
1 (7.7%)

Canine Distemper Virus + Adenovirus + Parvovirus Vaccine Adverse Event Insights

13 reports name Canine Distemper Virus + Adenovirus + Parvovirus Vaccine; 1 recorded a death outcome (7.7% of reported events, not a population-level mortality rate). Active ingredient: Canine Distemper Virus + Adenovirus + Parvovirus Vaccine. Administration routes: Unknown, Parenteral, Subcutaneous.

By species: Dog (13 reports). By breed: Terrier - Yorkshire (2), Terrier (unspecified) (2), Akita (1).

Leading clinical signs: Other abnormal test result NOS (4), Weight loss (2), Hypoproteinaemia (2), Hyperphosphataemia (2). Outcome, 13 coded reports: Ongoing leads at 46.2%.

Read these counts as reporting volume, not risk: per our methodology, a widely-prescribed drug will rack up more raw FDA reports in a given year than a rarely-used one at an identical true rate, so we recommend comparing within similar-exposure products rather than across the full 2025 catalog.

Source: FDA Center for Veterinary Medicine openFDA Animal & Veterinary Adverse Events (CVM AER) · 2025

Every figure on PlainBreed is rendered directly from FDA openFDA adverse event data, no number is typed in by an editor. This page draws directly on FDA openFDA data, no figure is typed in by an editor. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.